Organization
Pfizer Inc, Collegeville
1 abstract
Abstract
A SAFETY ANALYSIS OF TOFACITINIB 5 MG TWICE DAILY ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BACKGROUND CONVENTIONAL SYNTHETIC DMARDS IN A PHASE 3 RHEUMATOID ARTHRITIS POPULATION Org: Altoona Center for Clinical Research, Duncansville, United States, Institut de Rhumatologie de Montréal, Montréal, Canada, Sarasota Arthritis Research Center, Sarasota, Pfizer Inc, Collegeville, Pfizer Inc, Groton,